Risk Factors for Lymphedema in a Prospective Breast Cancer Survivorship Study: the Pathways Study

Overview

Journal Arch Surg

Publisher American Medical Association

Specialty General Surgery

Date 2010 Nov 17

PMID 21079093

Citations 69

Authors

Marilyn L Kwan

Jeanne Darbinian

Kathryn H Schmitz

Rebecca Citron

Paula Partee

Susan E Kutner

Lawrence H Kushi

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the incidence of breast cancer-related lymphedema (BCRL) during the early survivorship period as well as demographic, lifestyle, and clinical factors associated with BCRL development.

Design: The Pathways Study, a prospective cohort study of breast cancer survivors with a mean follow-up time of 20.9 months.

Setting: Kaiser Permanente Northern California medical care program.

Participants: We studied 997 women diagnosed from January 9, 2006, through October 15, 2007, with primary invasive breast cancer and who were at least 21 years of age at diagnosis, had no history of any cancer, and spoke English, Spanish, Cantonese, or Mandarin.

Main Outcome Measure: Clinical indication for BCRL as determined from outpatient or hospitalization diagnostic codes, outpatient procedural codes, and durable medical equipment orders.

Results: A clinical indication for BCRL was found in 133 women (13.3%), with a mean time to diagnosis of 8.3 months (range, 0.7-27.3 months). Being African American (hazard ratio, 1.93; 95% confidence interval, 1.00-3.72) or more educated (P for trend = .03) was associated with an increased risk of BCRL. Removal of at least 1 lymph node (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07) was associated with an increased risk, yet no significant association was observed for type of lymph node surgery. Being obese at breast cancer diagnosis was suggestive of an elevated risk (hazard ratio, 1.43; 95% confidence interval, 0.88-2.31).

Conclusions: In a large cohort study, BCRL occurs among a substantial proportion of early breast cancer survivors. Our findings agree with those of previous studies on the increased risk of BCRL with removal of lymph nodes and being obese, but they point to a differential risk according to race or ethnicity.

Citing Articles

Predictors of the Efficacy of Lymphedema Decongestive Therapy.

Dzupina A, Yaluri N, Singh J, Jankajova M Medicina (Kaunas). 2025; 61(2).

PMID: 40005348 PMC: 11857323. DOI: 10.3390/medicina61020231.

The influence of non-cancer-related risk factors on the development of cancer-related lymphedema: a rapid review.

Stout N, Dierkes M, Oliveri J, Rockson S, Paskett E Med Oncol. 2024; 41(11):274.

PMID: 39400761 DOI: 10.1007/s12032-024-02474-7.

Comprehensive strategies in breast cancer-related lymphedema prevention: insights from a multifaceted program.

Bhimani F, McEvoy M, Chen Y, Gupta A, Pastoriza J, Cavalli A Front Oncol. 2024; 14:1418610.

PMID: 39081716 PMC: 11286467. DOI: 10.3389/fonc.2024.1418610.

The role of breast cancer-related arm lymphedema in physical functioning and physical activity participation among long-term African American breast cancer survivors.

Nechuta S, Chen W, Goerge A, Boopathy D, Sanderson M Support Care Cancer. 2024; 32(7):446.

PMID: 38900224 PMC: 11368064. DOI: 10.1007/s00520-024-08648-3.

Bibliometric analysis of breast cancer-related lymphedema research trends over the last 2 decades.

Huang J, Li J, Li Y, Huang L, Li B, Huang F Front Oncol. 2024; 14:1360899.

PMID: 38444687 PMC: 10912165. DOI: 10.3389/fonc.2024.1360899.

References

Brorson H . Adipose tissue in lymphedema: the ignorance of adipose tissue in lymphedema. Lymphology. 2005; 37(4):175-7. View

Petrek J, PRESSMAN P, Smith R . Lymphedema: current issues in research and management. CA Cancer J Clin. 2000; 50(5):292-307; quiz 308-11. DOI: 10.3322/canjclin.50.5.292. View

Eversley R, Estrin D, Dibble S, Wardlaw L, Pedrosa M, Favila-Penney W . Post-treatment symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum. 2005; 32(2):250-6. DOI: 10.1188/05.ONF.250-256. View

Yen T, Fan X, Sparapani R, Laud P, Walker A, Nattinger A . A contemporary, population-based study of lymphedema risk factors in older women with breast cancer. Ann Surg Oncol. 2009; 16(4):979-88. PMC: 2729500. DOI: 10.1245/s10434-009-0347-2. View

Harris S . Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports. J Surg Oncol. 2000; 74(2):95-8; discussion 98-9. DOI: 10.1002/1096-9098(200006)74:2<95::AID-JSO3>3.0.CO;2-Q. View

McKenzie D, Kalda A . Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. J Clin Oncol. 2003; 21(3):463-6. DOI: 10.1200/JCO.2003.04.069. View

Madsen A, Haugaard K, Soerensen J, Bokmand S, Friis E, Holtveg H . Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast. 2007; 17(2):138-47. DOI: 10.1016/j.breast.2007.08.006. View

Cheville A, McGarvey C, Petrek J, Russo S, Thiadens S, Taylor M . The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol. 2003; 13(3):214-25. DOI: 10.1016/S1053-4296(03)00038-9. View

McLaughlin S, Wright M, Morris K, Giron G, Sampson M, Brockway J . Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008; 26(32):5213-9. PMC: 2652091. DOI: 10.1200/JCO.2008.16.3725. View

10.

Walsh D, Avashia J . Glucocorticoids in clinical oncology. Cleve Clin J Med. 1992; 59(5):505-15. DOI: 10.3949/ccjm.59.5.505. View

11.

Paskett E, Naughton M, McCoy T, Case L, Abbott J . The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007; 16(4):775-82. PMC: 4771019. DOI: 10.1158/1055-9965.EPI-06-0168. View

12.

Cochran A, Roberts A, Saida T . The place of lymphatic mapping and sentinel node biopsy in oncology. Int J Clin Oncol. 2003; 8(3):139-50. DOI: 10.1007/s10147-003-0333-9. View

13.

Helms G, Kuhn T, Moser L, Remmel E, Kreienberg R . Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection--data from a prospective randomised trial. Eur J Surg Oncol. 2008; 35(7):696-701. DOI: 10.1016/j.ejso.2008.06.013. View

14.

Humble C . Lymphedema: incidence, pathophysiology, management, and nursing care. Oncol Nurs Forum. 1995; 22(10):1503-9; quiz 1510-1. View

15.

Schmitz K, Ahmed R, Troxel A, Cheville A, Smith R, Lewis-Grant L . Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009; 361(7):664-73. DOI: 10.1056/NEJMoa0810118. View

16.

Kwan W, Jackson J, Weir L, Dingee C, McGregor G, Olivotto I . Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002; 20(20):4242-8. DOI: 10.1200/JCO.2002.09.018. View

17.

Staten L, Taren D, Howell W, Tobar M, Poehlman E, Hill A . Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc. 2001; 33(11):1959-67. DOI: 10.1097/00005768-200111000-00024. View

18.

Purushotham A, Upponi S, Klevesath M, Bobrow L, Millar K, Myles J . Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005; 23(19):4312-21. DOI: 10.1200/JCO.2005.03.228. View

19.

Francis W, Abghari P, Du W, Rymal C, Suna M, Kosir M . Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg. 2006; 192(5):636-9. DOI: 10.1016/j.amjsurg.2006.08.018. View

20.

Soran A, DAngelo G, Begovic M, Ardic F, Harlak A, Wieand H . Breast cancer-related lymphedema--what are the significant predictors and how they affect the severity of lymphedema?. Breast J. 2007; 12(6):536-43. DOI: 10.1111/j.1524-4741.2006.00342.x. View